TABLE 2.
Univariate and multivariate Cox regression analysis for disease-free survival.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, years | ||||
| <50 | 1 | |||
| ≥50 | 0.55 (0.33–0.9) | 0.018 | 0.45 (0.25–0.81) | 0.008 |
| Clinical stage | ||||
| I | 1 | |||
| II | 1.26 (0.55–2.86) | 0.586 | 0.98 (0.42–2.27) | 0.957 |
| III | 5.09 (2.29–11.31) | <0.001 | 3.83 (1.58–9.3) | 0.003 |
| IV | 129.75 (40.19–418.89) | <0.001 | 157.17 (43.63–566.12) | <0.001 |
| Histologic type | ||||
| Invasive ductal carcinoma | 1 | 1 | ||
| Invasive lobular carcinoma | 3.52 (1.27–9.72) | 0.015 | 1.54 (0.51–4.61) | 0.441 |
| Metaplastic carcinoma | 0 (0– Inf) | 0.997 | 0 (0–Inf) | 0.998 |
| Other | 0 (0– Inf) | 0.996 | 0 (0–Inf) | 0.997 |
| Histologic grade | ||||
| 1–2 | 1 | |||
| 3 | 0.95 (0.51–1.78) | 0.874 | ||
| Lymphovascular invasion | ||||
| No | 1 | 1 | ||
| Yes | 1.69 (1.03–2.78) | 0.039 | 1.65 (0.97–2.79) | 0.066 |
| Chemotherapy | ||||
| No | 1 | |||
| Yes | 0.67 (0.27–1.68) | 0.396 | ||
| Radiotherapy | ||||
| No | 1 | |||
| Yes | 1.88 (1.09–3.22) | 0.022 | 0.97 (0.51–1.83) | 0.915 |
| IHC-based molecular subtype | ||||
| IM | 1 | 1 | ||
| LAR | 1.97 (0.74–5.26) | 0.174 | 1.27 (0.46–3.49) | 0.642 |
| BLIS | 2.21 (0.93–5.25) | 0.072 | 1.28 (0.52–3.13) | 0.596 |
| MES | 0 (0– Inf) | 0.997 | 0 (0–Inf) | 0.996 |
| UC | 2.5 (0.89–7.05) | 0.083 | 1.5 (0.51–4.43) | 0.467 |
HR, hazard ratio; IHC, immunohistochemistry; BLIS, basal-like immunosuppressed; IM, immunomodulatory; LAR, luminal androgen receptor; MES, mesenchymal-like; UC, unclassifiable.